|
|
|
European Biopharmaceutical Review
|
|
There is little doubt that biomarkers will be one of the major drivers of pharmaceutical and diagnostics research and development (R&D) in the next decade. The post-genomic sciences have identified numerous potential drug targets, opening the door to many novel therapeutics. However, this has made bridging the gap between drug discovery and clinical development more challenging than ever. By predicting the potential success of therapies in clinical trials, biomarkers have the potential to improve research efficiency, save on development costs and provide organisations with a valuable advantage over competitors. Increasingly, biomarkers will be used in decision-making throughout the development pipeline and in disease management once therapies are in the clinic. However, before the full benefits of biomarkers can be realised, there are various challenges to overcome.
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” (1). Many types of biomarkers exist, including RNA, DNA, metabolites and proteins. For any particular research and development programme, the type of biomarker that best fits the purpose is often easy to identify, but the exact biomarker (or, indeed biomarkers) to use must first be discovered and then validated. Although the terms diagnostic and diagnostic test are frequently used interchangeably with biomarker and biomarker testing, biomarkers can only become diagnostics following the collection of much qualifying data, and the development of an easy-to-use testing kit.
Using biomarkers is considered a key approach to increasing productivity and decreasing costs in the pharmaceutical industry. Biomarkers have roles spanning all aspects of drug discovery and development, from research tools to clinical endpoints. Some biomarkers can help diagnose the state of a person’s biology and others have prognostic potential. In addition, biomarkers are vital to realising the goal of personalised medicine. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Dr Ruth A VanBogelen is Director of Biomarkers and Proteomics at NextGen Sciences. She has 30 years’ experience using proteomics technologies to generate and test hypotheses for preclinical and clinical programmes, in both industry and academia, and has also led research into microbial proteomics at the University of Michigan Medical Centre. Ruth has published over 30 peer-reviewed scientific papers and has authored numerous review articles and book chapters on proteomics. She currently serves on the Editorial Board for Proteomics, Proteomics Clinical Applications and the Journal of Proteomics and Bioinformatics.
Dr M Walid Qoronfleh is Vice President of Business Development at NextGen Sciences. He has over 20 years’ commercial experience, with responsibilities including strategic planning, scientific direction, business development and marketing and sales strategy. Walid has held several senior management and executive positions with an emphasis on product development, commercialisation and portfolio management, as well as scientific, R&D and technology appointments. Walid received an MBA from Penn State University and has a Marketing certificate from the University of Wisconsin- Madison. |
|
|
|
|
|
 |
News and Press Releases |
 |
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
Basel, March 16, 2023 — Novartis today announced the U.S. Food and Drug Administration (FDA) granted approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age. These approvals make Tafinlar + Mekinist the first and only approved combination targeted therapy to treat pediatric patients with BRAF V600E LGG.
More info >> |
|
 |
White Papers |
 |
|
Medpace Reference Laboratories establishes state of the art Flow Cytometry techniques for flexible approaches to clinical trials across multiple therapeutic areas.
Medpace
Cytometry is the process of measuring the properties of individual cells. These properties may include gene or protein expression, chemical properties, deoxyribonucleic acid (DNA) content, and various cellular functions. The earliest methods of cytometry relied upon light microscopy for the classification and observation of cells and cellular components. Microscopy permitted direct visual observation of cells for the first time, leading to the classification of cells by morphology and insight into cellular functions. However, the time required for microscopic analysis constrains the number of samples or number of cells in each sample that can be examined. Therefore, the utility of microscopy for analysis of rare cells or in situations where sample throughput is a priority is limited. Flow cytometry was developed largely to improve upon these limitations.
More info >> |
|
|
